Active	Status	Sponsor type	Region	Phase	Filter
11 Active 9 Inactive 20 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Klein, Pavel
NCT06453213: Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy	Not yet recruiting	4	90	US	Cenobamate	SK Life Science, Inc.	Focal Onset Seizure	05/27	07/27
TrustTSC, NCT05323734 / 2021-003441-38: Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy	Active, not recruiting	3	128	Europe, Canada, US, RoW	Ganaxalone, Placebo	Marinus Pharmaceuticals, Marinus Pharmaceuticals Inc., Marinus Pharmaceuticals, Inc.	Tuberous Sclerosis Complex	10/24	10/24
NCT05219617: Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults	Recruiting	3	252	Europe, US, RoW	Carisbamate	SK Life Science, Inc.	Seizures, Lennox Gastaut Syndrome	06/25	06/26
NCT04938427 / 2021-002481-40: A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome	Completed	3	270	Europe, Canada, Japan, US, RoW	Soticlestat, TAK-935, Placebo	Takeda	Lennox Gastaut Syndrome (LGS)	01/24	01/24
NCT05067634 / 2020-005344-27: Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures	Recruiting	3	140	Europe, US, RoW	Xcopri	SK Life Science, Inc.	Partial Epilepsy	05/26	07/26
ENDYMION 2, NCT05163314 / 2021-002482-17: A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome	Recruiting	3	400	Europe, Canada, Japan, US, RoW	Soticlestat, TAK-935	Takeda	Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)	05/26	05/26
NCT05668754: Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH	Active, not recruiting	2	48	US	Serdexmethylphenidate, SDX, Placebo	Zevra Therapeutics, Rho, Inc.	Idiopathic Hypersomnia	06/24	06/24
NCT04244175: A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures	Active, not recruiting	2	154	Europe, US, RoW	CVL-865, Placebo	Cerevel Therapeutics, LLC	Seizures	05/24	07/24
NCT05473442: Study of EQU-001 for Uncontrolled Focal Onset Seizures	Terminated	2	27	US, RoW	EQU-001, Matching Placebo	Equilibre Biopharmaceuticals B.V.	Focal Onset Seizures	07/23	07/23
NCT04903314: Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures	Recruiting	1	24	US, RoW	Xcopri	SK Life Science, Inc.	Partial Epilepsy	07/24	10/24
NCT04879433: Prospective Open-label Evaluation of Cenobamate Adjunctive Treatment of Adults With Refractory Focal Epilepsy	Recruiting	N/A	100	US		Mid-Atlantic Epilepsy and Sleep Center, LLC	Focal Epilepsy	06/23	11/23